DOP040: Postoperative surgical recurrence in Crohn’s Disease decreases significantly in the biologic eraECCO'17 Barcelona 2017
1
DOP041: Prepouch ileitis after ileal pouch anal anastomosis for Ulcerative Colitis: Patterns of presentation and risk factors for failure of treatmentECCO'17 Barcelona 2017
1
DOP042: Omentectomy is not necessary during laparoscopic total coloproctectomy and ileal Pouch-anal anastomosis for inflammatory bowel disease. A comparative study in 247 consecutive patients from 4 expert centresECCO'17 Barcelona 2017
1
DOP043: High risk of pouch dysplasia in IBD-PSC patients following total proctocolectomyECCO'17 Barcelona 2017
1
DOP044: Relationship between microbiota and development of early postoperative Crohn’s Disease recurrenceECCO'17 Barcelona 2017
1
DOP046: Genome-wide association study of baseline disease characteristics and response to Ustekinumab in moderate to severe Crohn’s DiseaseECCO'17 Barcelona 2017
1
DOP047: Early fibrostenosis in Crohn’s Disease is associated with multiple susceptibility loci on Immunochip analysisECCO'17 Barcelona 2017
1
DOP048: PROFILE trial: Predicting outcomes for Crohn’s Disease using a molecular biomarkerECCO'17 Barcelona 2017
1
DOP049: Inflammatory dyskinesis: defects of NF-κ B dynamic behaviour as a new potential biomarker for personalized medicine in Inflammatory Bowel DiseaseECCO'17 Barcelona 2017
1
DOP051: Serological biomarkers of tissue turnover can early identify responders to infliximab in Crohn’s DiseaseECCO'17 Barcelona 2017
1
DOP052: Molecular response to Ustekinumab in moderate-to-severe Crohn’s Disease by serum protein and biopsy gene expression analysis: Results from Ustekinumab phase 3 studiesECCO'17 Barcelona 2017
1
DOP055: Results of the Fifth Scientific Workshop of the ECCO (II): Clinical aspects of perianal fistulising Crohn’s Disease - The unmet needsECCO'17 Barcelona 2017
1
DOP057: Perianal pediatric Crohn's Disease is associated with a distinct phenotype and greater inflammatory burdenECCO'17 Barcelona 2017
1
DOP058: Does biologic therapy increase the risk for fistula-associated mucinous adenocarcinoma in long standing perianal Crohn’s Disease?ECCO'17 Barcelona 2017
1
DOP060: Real-world treatment pathway visualizations show low use of biologic therapies in Crohn’s Disease and Ulcerative Colitis in the United StatesECCO'17 Barcelona 2017
1
DOP062: Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: Explorative IBD subgroup-analyses in Crohn’s Disease and ulcerative colitis from the NOR-SWITCH trialECCO'17 Barcelona 2017
1